0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Manmade Version of Somatostatin Market Research Report 2024
Published Date: October 2024
|
Report Code: QYRE-Auto-31J18254
Home | Market Reports | Science| Biological Sciences
Global Manmade Version of Somatostatin Market Research Report 2024
BUY CHAPTERS

Global Manmade Version of Somatostatin Market Research Report 2024

Code: QYRE-Auto-31J18254
Report
October 2024
Pages:101
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Manmade Version of Somatostatin Market Size

The global Manmade Version of Somatostatin market was valued at US$ 6595 million in 2023 and is anticipated to reach US$ 10500 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.

Manmade Version of Somatostatin Market

Manmade Version of Somatostatin Market

The manmade version of somatostatin refers to synthetic analogues of the naturally occurring hormone somatostatin, designed to replicate its biological effects in the body. These synthetic versions, such as octreotide and lanreotide, are engineered to have enhanced stability, prolonged action, and improved pharmacokinetic profiles compared to natural somatostatin. They are primarily used in medical applications to inhibit the secretion of various hormones, making them effective treatments for conditions like acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders.
The market for manmade versions of somatostatin, particularly synthetic analogues like octreotide and lanreotide, is experiencing steady growth, primarily driven by the increasing prevalence of hormone-related disorders such as acromegaly and neuroendocrine tumors.
Recent advancements in formulation technology have further boosted the market for these synthetic analogues. Long-acting formulations allow for less frequent dosing, improving patient compliance and convenience. This shift towards sustained-release options has made treatment regimens easier to manage, leading to greater acceptance among both patients and healthcare providers. Additionally, ongoing research into new indications and combinations with other therapies is expanding the therapeutic potential of manmade somatostatin analogues, enhancing their market appeal.
Moreover, the growing trend towards personalized medicine is influencing the adoption of manmade somatostatin analogues. Healthcare providers are increasingly focusing on tailoring treatments to individual patient needs, making these targeted therapies particularly valuable. As clinical guidelines evolve and integrate these analogues into broader treatment strategies, the market is expected to continue expanding, supported by an increasing range of indications and ongoing innovations in drug development.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Manmade Version of Somatostatin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Manmade Version of Somatostatin.
The Manmade Version of Somatostatin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Manmade Version of Somatostatin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Manmade Version of Somatostatin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Manmade Version of Somatostatin Market Report

Report Metric Details
Report Name Manmade Version of Somatostatin Market
Accounted market size in 2023 US$ 6595 million
Forecasted market size in 2030 US$ 10500 million
CAGR 6.9%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Ipsen, Recordati Rare Diseases, Chiesi Farmaceutici S.p.A, Advanz Pharma, Cipla, Teva, Gland Pharma, Heritage Pharmaceuticals, Sagent Pharmaceuticals, Sun Pharmaceutical, Fresenius Kabi, Mylan, West-Ward Pharmaceuticals, Suzhou Tianma Pharmaceutical, Sihuan Pharmaceutical, Chengdu Tiantaishan pharmaceutical, Hybio Pharmaceutical, Hainan Shuangcheng Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Manmade Version of Somatostatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Manmade Version of Somatostatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Manmade Version of Somatostatin Market growing?

Ans: The Manmade Version of Somatostatin Market witnessing a CAGR of 6.9% during the forecast period 2024-2030.

What is the Manmade Version of Somatostatin Market size in 2030?

Ans: The Manmade Version of Somatostatin Market size in 2030 will be US$ 10500 million.

Who are the main players in the Manmade Version of Somatostatin Market report?

Ans: The main players in the Manmade Version of Somatostatin Market are Novartis, Ipsen, Recordati Rare Diseases, Chiesi Farmaceutici S.p.A, Advanz Pharma, Cipla, Teva, Gland Pharma, Heritage Pharmaceuticals, Sagent Pharmaceuticals, Sun Pharmaceutical, Fresenius Kabi, Mylan, West-Ward Pharmaceuticals, Suzhou Tianma Pharmaceutical, Sihuan Pharmaceutical, Chengdu Tiantaishan pharmaceutical, Hybio Pharmaceutical, Hainan Shuangcheng Pharmaceuticals

What are the Application segmentation covered in the Manmade Version of Somatostatin Market report?

Ans: The Applications covered in the Manmade Version of Somatostatin Market report are Neuroendocrine Tumors, Acromegaly, Cushing Syndrome, Other

What are the Type segmentation covered in the Manmade Version of Somatostatin Market report?

Ans: The Types covered in the Manmade Version of Somatostatin Market report are Octreotide, Lanreotide, Pasireotide, Other

Recommended Reports

Somatostatin & Analogs

Endocrine & Hormone Drugs

Neuroendocrine Tumor Market

1 Manmade Version of Somatostatin Market Overview
1.1 Product Definition
1.2 Manmade Version of Somatostatin by Type
1.2.1 Global Manmade Version of Somatostatin Market Value Comparison by Type (2024-2030)
1.2.2 Octreotide
1.2.3 Lanreotide
1.2.4 Pasireotide
1.2.5 Other
1.3 Manmade Version of Somatostatin by Application
1.3.1 Global Manmade Version of Somatostatin Market Value by Application (2024-2030)
1.3.2 Neuroendocrine Tumors
1.3.3 Acromegaly
1.3.4 Cushing Syndrome
1.3.5 Other
1.4 Global Manmade Version of Somatostatin Market Size Estimates and Forecasts
1.4.1 Global Manmade Version of Somatostatin Revenue 2019-2030
1.4.2 Global Manmade Version of Somatostatin Sales 2019-2030
1.4.3 Global Manmade Version of Somatostatin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Manmade Version of Somatostatin Market Competition by Manufacturers
2.1 Global Manmade Version of Somatostatin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Manmade Version of Somatostatin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Manmade Version of Somatostatin Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Manmade Version of Somatostatin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Manmade Version of Somatostatin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Manmade Version of Somatostatin, Product Type & Application
2.7 Global Key Manufacturers of Manmade Version of Somatostatin, Date of Enter into This Industry
2.8 Global Manmade Version of Somatostatin Market Competitive Situation and Trends
2.8.1 Global Manmade Version of Somatostatin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Manmade Version of Somatostatin Players Market Share by Revenue
2.8.3 Global Manmade Version of Somatostatin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Manmade Version of Somatostatin Market Scenario by Region
3.1 Global Manmade Version of Somatostatin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Manmade Version of Somatostatin Sales by Region: 2019-2030
3.2.1 Global Manmade Version of Somatostatin Sales by Region: 2019-2024
3.2.2 Global Manmade Version of Somatostatin Sales by Region: 2025-2030
3.3 Global Manmade Version of Somatostatin Revenue by Region: 2019-2030
3.3.1 Global Manmade Version of Somatostatin Revenue by Region: 2019-2024
3.3.2 Global Manmade Version of Somatostatin Revenue by Region: 2025-2030
3.4 North America Manmade Version of Somatostatin Market Facts & Figures by Country
3.4.1 North America Manmade Version of Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Manmade Version of Somatostatin Sales by Country (2019-2030)
3.4.3 North America Manmade Version of Somatostatin Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Manmade Version of Somatostatin Market Facts & Figures by Country
3.5.1 Europe Manmade Version of Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Manmade Version of Somatostatin Sales by Country (2019-2030)
3.5.3 Europe Manmade Version of Somatostatin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Manmade Version of Somatostatin Market Facts & Figures by Region
3.6.1 Asia Pacific Manmade Version of Somatostatin Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Manmade Version of Somatostatin Sales by Region (2019-2030)
3.6.3 Asia Pacific Manmade Version of Somatostatin Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Manmade Version of Somatostatin Market Facts & Figures by Country
3.7.1 Latin America Manmade Version of Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Manmade Version of Somatostatin Sales by Country (2019-2030)
3.7.3 Latin America Manmade Version of Somatostatin Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Manmade Version of Somatostatin Market Facts & Figures by Country
3.8.1 Middle East and Africa Manmade Version of Somatostatin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Manmade Version of Somatostatin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Manmade Version of Somatostatin Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Manmade Version of Somatostatin Sales by Type (2019-2030)
4.1.1 Global Manmade Version of Somatostatin Sales by Type (2019-2024)
4.1.2 Global Manmade Version of Somatostatin Sales by Type (2025-2030)
4.1.3 Global Manmade Version of Somatostatin Sales Market Share by Type (2019-2030)
4.2 Global Manmade Version of Somatostatin Revenue by Type (2019-2030)
4.2.1 Global Manmade Version of Somatostatin Revenue by Type (2019-2024)
4.2.2 Global Manmade Version of Somatostatin Revenue by Type (2025-2030)
4.2.3 Global Manmade Version of Somatostatin Revenue Market Share by Type (2019-2030)
4.3 Global Manmade Version of Somatostatin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Manmade Version of Somatostatin Sales by Application (2019-2030)
5.1.1 Global Manmade Version of Somatostatin Sales by Application (2019-2024)
5.1.2 Global Manmade Version of Somatostatin Sales by Application (2025-2030)
5.1.3 Global Manmade Version of Somatostatin Sales Market Share by Application (2019-2030)
5.2 Global Manmade Version of Somatostatin Revenue by Application (2019-2030)
5.2.1 Global Manmade Version of Somatostatin Revenue by Application (2019-2024)
5.2.2 Global Manmade Version of Somatostatin Revenue by Application (2025-2030)
5.2.3 Global Manmade Version of Somatostatin Revenue Market Share by Application (2019-2030)
5.3 Global Manmade Version of Somatostatin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Manmade Version of Somatostatin Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Ipsen
6.2.1 Ipsen Company Information
6.2.2 Ipsen Description and Business Overview
6.2.3 Ipsen Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ipsen Manmade Version of Somatostatin Product Portfolio
6.2.5 Ipsen Recent Developments/Updates
6.3 Recordati Rare Diseases
6.3.1 Recordati Rare Diseases Company Information
6.3.2 Recordati Rare Diseases Description and Business Overview
6.3.3 Recordati Rare Diseases Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Recordati Rare Diseases Manmade Version of Somatostatin Product Portfolio
6.3.5 Recordati Rare Diseases Recent Developments/Updates
6.4 Chiesi Farmaceutici S.p.A
6.4.1 Chiesi Farmaceutici S.p.A Company Information
6.4.2 Chiesi Farmaceutici S.p.A Description and Business Overview
6.4.3 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product Portfolio
6.4.5 Chiesi Farmaceutici S.p.A Recent Developments/Updates
6.5 Advanz Pharma
6.5.1 Advanz Pharma Company Information
6.5.2 Advanz Pharma Description and Business Overview
6.5.3 Advanz Pharma Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Advanz Pharma Manmade Version of Somatostatin Product Portfolio
6.5.5 Advanz Pharma Recent Developments/Updates
6.6 Cipla
6.6.1 Cipla Company Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Cipla Manmade Version of Somatostatin Product Portfolio
6.6.5 Cipla Recent Developments/Updates
6.7 Teva
6.7.1 Teva Company Information
6.7.2 Teva Description and Business Overview
6.7.3 Teva Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Teva Manmade Version of Somatostatin Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Gland Pharma
6.8.1 Gland Pharma Company Information
6.8.2 Gland Pharma Description and Business Overview
6.8.3 Gland Pharma Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Gland Pharma Manmade Version of Somatostatin Product Portfolio
6.8.5 Gland Pharma Recent Developments/Updates
6.9 Heritage Pharmaceuticals
6.9.1 Heritage Pharmaceuticals Company Information
6.9.2 Heritage Pharmaceuticals Description and Business Overview
6.9.3 Heritage Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Heritage Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
6.9.5 Heritage Pharmaceuticals Recent Developments/Updates
6.10 Sagent Pharmaceuticals
6.10.1 Sagent Pharmaceuticals Company Information
6.10.2 Sagent Pharmaceuticals Description and Business Overview
6.10.3 Sagent Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sagent Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
6.10.5 Sagent Pharmaceuticals Recent Developments/Updates
6.11 Sun Pharmaceutical
6.11.1 Sun Pharmaceutical Company Information
6.11.2 Sun Pharmaceutical Description and Business Overview
6.11.3 Sun Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sun Pharmaceutical Manmade Version of Somatostatin Product Portfolio
6.11.5 Sun Pharmaceutical Recent Developments/Updates
6.12 Fresenius Kabi
6.12.1 Fresenius Kabi Company Information
6.12.2 Fresenius Kabi Description and Business Overview
6.12.3 Fresenius Kabi Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Fresenius Kabi Manmade Version of Somatostatin Product Portfolio
6.12.5 Fresenius Kabi Recent Developments/Updates
6.13 Mylan
6.13.1 Mylan Company Information
6.13.2 Mylan Description and Business Overview
6.13.3 Mylan Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Mylan Manmade Version of Somatostatin Product Portfolio
6.13.5 Mylan Recent Developments/Updates
6.14 West-Ward Pharmaceuticals
6.14.1 West-Ward Pharmaceuticals Company Information
6.14.2 West-Ward Pharmaceuticals Description and Business Overview
6.14.3 West-Ward Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.14.4 West-Ward Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
6.14.5 West-Ward Pharmaceuticals Recent Developments/Updates
6.15 Suzhou Tianma Pharmaceutical
6.15.1 Suzhou Tianma Pharmaceutical Company Information
6.15.2 Suzhou Tianma Pharmaceutical Description and Business Overview
6.15.3 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product Portfolio
6.15.5 Suzhou Tianma Pharmaceutical Recent Developments/Updates
6.16 Sihuan Pharmaceutical
6.16.1 Sihuan Pharmaceutical Company Information
6.16.2 Sihuan Pharmaceutical Description and Business Overview
6.16.3 Sihuan Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Sihuan Pharmaceutical Manmade Version of Somatostatin Product Portfolio
6.16.5 Sihuan Pharmaceutical Recent Developments/Updates
6.17 Chengdu Tiantaishan pharmaceutical
6.17.1 Chengdu Tiantaishan pharmaceutical Company Information
6.17.2 Chengdu Tiantaishan pharmaceutical Description and Business Overview
6.17.3 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product Portfolio
6.17.5 Chengdu Tiantaishan pharmaceutical Recent Developments/Updates
6.18 Hybio Pharmaceutical
6.18.1 Hybio Pharmaceutical Company Information
6.18.2 Hybio Pharmaceutical Description and Business Overview
6.18.3 Hybio Pharmaceutical Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Hybio Pharmaceutical Manmade Version of Somatostatin Product Portfolio
6.18.5 Hybio Pharmaceutical Recent Developments/Updates
6.19 Hainan Shuangcheng Pharmaceuticals
6.19.1 Hainan Shuangcheng Pharmaceuticals Company Information
6.19.2 Hainan Shuangcheng Pharmaceuticals Description and Business Overview
6.19.3 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product Portfolio
6.19.5 Hainan Shuangcheng Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Manmade Version of Somatostatin Industry Chain Analysis
7.2 Manmade Version of Somatostatin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Manmade Version of Somatostatin Production Mode & Process
7.4 Manmade Version of Somatostatin Sales and Marketing
7.4.1 Manmade Version of Somatostatin Sales Channels
7.4.2 Manmade Version of Somatostatin Distributors
7.5 Manmade Version of Somatostatin Customers
8 Manmade Version of Somatostatin Market Dynamics
8.1 Manmade Version of Somatostatin Industry Trends
8.2 Manmade Version of Somatostatin Market Drivers
8.3 Manmade Version of Somatostatin Market Challenges
8.4 Manmade Version of Somatostatin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Manmade Version of Somatostatin Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Manmade Version of Somatostatin Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Manmade Version of Somatostatin Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Manmade Version of Somatostatin Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Manmade Version of Somatostatin Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Manmade Version of Somatostatin Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Manmade Version of Somatostatin Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Manmade Version of Somatostatin Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Manmade Version of Somatostatin, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Manmade Version of Somatostatin, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Manmade Version of Somatostatin, Product Type & Application
 Table 12. Global Key Manufacturers of Manmade Version of Somatostatin, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Manmade Version of Somatostatin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Manmade Version of Somatostatin as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Manmade Version of Somatostatin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Manmade Version of Somatostatin Sales by Region (2019-2024) & (K Units)
 Table 18. Global Manmade Version of Somatostatin Sales Market Share by Region (2019-2024)
 Table 19. Global Manmade Version of Somatostatin Sales by Region (2025-2030) & (K Units)
 Table 20. Global Manmade Version of Somatostatin Sales Market Share by Region (2025-2030)
 Table 21. Global Manmade Version of Somatostatin Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Manmade Version of Somatostatin Revenue Market Share by Region (2019-2024)
 Table 23. Global Manmade Version of Somatostatin Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Manmade Version of Somatostatin Revenue Market Share by Region (2025-2030)
 Table 25. North America Manmade Version of Somatostatin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Manmade Version of Somatostatin Sales by Country (2019-2024) & (K Units)
 Table 27. North America Manmade Version of Somatostatin Sales by Country (2025-2030) & (K Units)
 Table 28. North America Manmade Version of Somatostatin Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Manmade Version of Somatostatin Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Manmade Version of Somatostatin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Manmade Version of Somatostatin Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Manmade Version of Somatostatin Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Manmade Version of Somatostatin Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Manmade Version of Somatostatin Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Manmade Version of Somatostatin Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Manmade Version of Somatostatin Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Manmade Version of Somatostatin Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Manmade Version of Somatostatin Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Manmade Version of Somatostatin Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Manmade Version of Somatostatin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Manmade Version of Somatostatin Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Manmade Version of Somatostatin Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Manmade Version of Somatostatin Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Manmade Version of Somatostatin Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Manmade Version of Somatostatin Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Manmade Version of Somatostatin Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Manmade Version of Somatostatin Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Manmade Version of Somatostatin Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Manmade Version of Somatostatin Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Manmade Version of Somatostatin Sales (K Units) by Type (2019-2024)
 Table 51. Global Manmade Version of Somatostatin Sales (K Units) by Type (2025-2030)
 Table 52. Global Manmade Version of Somatostatin Sales Market Share by Type (2019-2024)
 Table 53. Global Manmade Version of Somatostatin Sales Market Share by Type (2025-2030)
 Table 54. Global Manmade Version of Somatostatin Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Manmade Version of Somatostatin Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Manmade Version of Somatostatin Revenue Market Share by Type (2019-2024)
 Table 57. Global Manmade Version of Somatostatin Revenue Market Share by Type (2025-2030)
 Table 58. Global Manmade Version of Somatostatin Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Manmade Version of Somatostatin Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Manmade Version of Somatostatin Sales (K Units) by Application (2019-2024)
 Table 61. Global Manmade Version of Somatostatin Sales (K Units) by Application (2025-2030)
 Table 62. Global Manmade Version of Somatostatin Sales Market Share by Application (2019-2024)
 Table 63. Global Manmade Version of Somatostatin Sales Market Share by Application (2025-2030)
 Table 64. Global Manmade Version of Somatostatin Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Manmade Version of Somatostatin Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Manmade Version of Somatostatin Revenue Market Share by Application (2019-2024)
 Table 67. Global Manmade Version of Somatostatin Revenue Market Share by Application (2025-2030)
 Table 68. Global Manmade Version of Somatostatin Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Manmade Version of Somatostatin Price (US$/Unit) by Application (2025-2030)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Novartis Manmade Version of Somatostatin Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Ipsen Company Information
 Table 76. Ipsen Description and Business Overview
 Table 77. Ipsen Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Ipsen Manmade Version of Somatostatin Product
 Table 79. Ipsen Recent Developments/Updates
 Table 80. Recordati Rare Diseases Company Information
 Table 81. Recordati Rare Diseases Description and Business Overview
 Table 82. Recordati Rare Diseases Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Recordati Rare Diseases Manmade Version of Somatostatin Product
 Table 84. Recordati Rare Diseases Recent Developments/Updates
 Table 85. Chiesi Farmaceutici S.p.A Company Information
 Table 86. Chiesi Farmaceutici S.p.A Description and Business Overview
 Table 87. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product
 Table 89. Chiesi Farmaceutici S.p.A Recent Developments/Updates
 Table 90. Advanz Pharma Company Information
 Table 91. Advanz Pharma Description and Business Overview
 Table 92. Advanz Pharma Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Advanz Pharma Manmade Version of Somatostatin Product
 Table 94. Advanz Pharma Recent Developments/Updates
 Table 95. Cipla Company Information
 Table 96. Cipla Description and Business Overview
 Table 97. Cipla Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Cipla Manmade Version of Somatostatin Product
 Table 99. Cipla Recent Developments/Updates
 Table 100. Teva Company Information
 Table 101. Teva Description and Business Overview
 Table 102. Teva Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Teva Manmade Version of Somatostatin Product
 Table 104. Teva Recent Developments/Updates
 Table 105. Gland Pharma Company Information
 Table 106. Gland Pharma Description and Business Overview
 Table 107. Gland Pharma Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Gland Pharma Manmade Version of Somatostatin Product
 Table 109. Gland Pharma Recent Developments/Updates
 Table 110. Heritage Pharmaceuticals Company Information
 Table 111. Heritage Pharmaceuticals Description and Business Overview
 Table 112. Heritage Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Heritage Pharmaceuticals Manmade Version of Somatostatin Product
 Table 114. Heritage Pharmaceuticals Recent Developments/Updates
 Table 115. Sagent Pharmaceuticals Company Information
 Table 116. Sagent Pharmaceuticals Description and Business Overview
 Table 117. Sagent Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Sagent Pharmaceuticals Manmade Version of Somatostatin Product
 Table 119. Sagent Pharmaceuticals Recent Developments/Updates
 Table 120. Sun Pharmaceutical Company Information
 Table 121. Sun Pharmaceutical Description and Business Overview
 Table 122. Sun Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Sun Pharmaceutical Manmade Version of Somatostatin Product
 Table 124. Sun Pharmaceutical Recent Developments/Updates
 Table 125. Fresenius Kabi Company Information
 Table 126. Fresenius Kabi Description and Business Overview
 Table 127. Fresenius Kabi Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Fresenius Kabi Manmade Version of Somatostatin Product
 Table 129. Fresenius Kabi Recent Developments/Updates
 Table 130. Mylan Company Information
 Table 131. Mylan Description and Business Overview
 Table 132. Mylan Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Mylan Manmade Version of Somatostatin Product
 Table 134. Mylan Recent Developments/Updates
 Table 135. West-Ward Pharmaceuticals Company Information
 Table 136. West-Ward Pharmaceuticals Description and Business Overview
 Table 137. West-Ward Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. West-Ward Pharmaceuticals Manmade Version of Somatostatin Product
 Table 139. West-Ward Pharmaceuticals Recent Developments/Updates
 Table 140. Suzhou Tianma Pharmaceutical Company Information
 Table 141. Suzhou Tianma Pharmaceutical Description and Business Overview
 Table 142. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product
 Table 144. Suzhou Tianma Pharmaceutical Recent Developments/Updates
 Table 145. Sihuan Pharmaceutical Company Information
 Table 146. Sihuan Pharmaceutical Description and Business Overview
 Table 147. Sihuan Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. Sihuan Pharmaceutical Manmade Version of Somatostatin Product
 Table 149. Sihuan Pharmaceutical Recent Developments/Updates
 Table 150. Chengdu Tiantaishan pharmaceutical Company Information
 Table 151. Chengdu Tiantaishan pharmaceutical Description and Business Overview
 Table 152. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 153. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product
 Table 154. Chengdu Tiantaishan pharmaceutical Recent Developments/Updates
 Table 155. Hybio Pharmaceutical Company Information
 Table 156. Hybio Pharmaceutical Description and Business Overview
 Table 157. Hybio Pharmaceutical Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 158. Hybio Pharmaceutical Manmade Version of Somatostatin Product
 Table 159. Hybio Pharmaceutical Recent Developments/Updates
 Table 160. Hainan Shuangcheng Pharmaceuticals Company Information
 Table 161. Hainan Shuangcheng Pharmaceuticals Description and Business Overview
 Table 162. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 163. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product
 Table 164. Hainan Shuangcheng Pharmaceuticals Recent Developments/Updates
 Table 165. Key Raw Materials Lists
 Table 166. Raw Materials Key Suppliers Lists
 Table 167. Manmade Version of Somatostatin Distributors List
 Table 168. Manmade Version of Somatostatin Customers List
 Table 169. Manmade Version of Somatostatin Market Trends
 Table 170. Manmade Version of Somatostatin Market Drivers
 Table 171. Manmade Version of Somatostatin Market Challenges
 Table 172. Manmade Version of Somatostatin Market Restraints
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Manmade Version of Somatostatin
 Figure 2. Global Manmade Version of Somatostatin Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Manmade Version of Somatostatin Market Share by Type: 2023 & 2030
 Figure 4. Octreotide Product Picture
 Figure 5. Lanreotide Product Picture
 Figure 6. Pasireotide Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Manmade Version of Somatostatin Market Value by Application (2024-2030) & (US$ Million)
 Figure 9. Global Manmade Version of Somatostatin Market Share by Application: 2023 & 2030
 Figure 10. Neuroendocrine Tumors
 Figure 11. Acromegaly
 Figure 12. Cushing Syndrome
 Figure 13. Other
 Figure 14. Global Manmade Version of Somatostatin Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Manmade Version of Somatostatin Market Size (2019-2030) & (US$ Million)
 Figure 16. Global Manmade Version of Somatostatin Sales (2019-2030) & (K Units)
 Figure 17. Global Manmade Version of Somatostatin Average Price (US$/Unit) & (2019-2030)
 Figure 18. Manmade Version of Somatostatin Report Years Considered
 Figure 19. Manmade Version of Somatostatin Sales Share by Manufacturers in 2023
 Figure 20. Global Manmade Version of Somatostatin Revenue Share by Manufacturers in 2023
 Figure 21. Global 5 and 10 Largest Manmade Version of Somatostatin Players: Market Share by Revenue in Manmade Version of Somatostatin in 2023
 Figure 22. Manmade Version of Somatostatin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 23. Global Manmade Version of Somatostatin Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 24. North America Manmade Version of Somatostatin Sales Market Share by Country (2019-2030)
 Figure 25. North America Manmade Version of Somatostatin Revenue Market Share by Country (2019-2030)
 Figure 26. United States Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Canada Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. Europe Manmade Version of Somatostatin Sales Market Share by Country (2019-2030)
 Figure 29. Europe Manmade Version of Somatostatin Revenue Market Share by Country (2019-2030)
 Figure 30. Germany Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. France Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. U.K. Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Italy Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Russia Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Asia Pacific Manmade Version of Somatostatin Sales Market Share by Region (2019-2030)
 Figure 36. Asia Pacific Manmade Version of Somatostatin Revenue Market Share by Region (2019-2030)
 Figure 37. China Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Japan Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. South Korea Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. India Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Australia Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. China Taiwan Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Southeast Asia Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Latin America Manmade Version of Somatostatin Sales Market Share by Country (2019-2030)
 Figure 45. Mexico Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Brazil Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Argentina Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Colombia Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Middle East and Africa Manmade Version of Somatostatin Sales Market Share by Country (2019-2030)
 Figure 50. Middle East and Africa Manmade Version of Somatostatin Revenue Market Share by Country (2019-2030)
 Figure 51. Turkey Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Saudi Arabia Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. UAE Manmade Version of Somatostatin Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 54. Global Sales Market Share of Manmade Version of Somatostatin by Type (2019-2030)
 Figure 55. Global Revenue Market Share of Manmade Version of Somatostatin by Type (2019-2030)
 Figure 56. Global Manmade Version of Somatostatin Price (US$/Unit) by Type (2019-2030)
 Figure 57. Global Sales Market Share of Manmade Version of Somatostatin by Application (2019-2030)
 Figure 58. Global Revenue Market Share of Manmade Version of Somatostatin by Application (2019-2030)
 Figure 59. Global Manmade Version of Somatostatin Price (US$/Unit) by Application (2019-2030)
 Figure 60. Manmade Version of Somatostatin Value Chain
 Figure 61. Manmade Version of Somatostatin Production Process
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS

RELATED REPORTS

Global Salt Active Nuclease Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6W17226
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Parietal Bone Model Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34V19460
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Genome Editing Enzymes Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6C20013
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Genome Editing Tool Enzymes Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37K19803
Thu Sep 11 00:00:00 UTC 2025

Add to Cart